Pramlintide

Drug Profile

Pramlintide

Alternative Names: AC-0137; AC-137; BMS-986114; Pramlintide acetate; SYMLIN; Tripro-amylin

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Amylin Pharmaceuticals
  • Developer AstraZeneca
  • Class Antihyperglycaemics; Macromolecular substances; Proteins
  • Mechanism of Action Islet amyloid polypeptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 01 Feb 2014 AstraZeneca acquires pramlintide from Bristol-Myers Squibb
  • 09 Aug 2012 Bristol-Myers Squibb and AstraZeneca expand diabetes collaboration to cover co-development and marketing of pramlintide
  • 08 Aug 2012 Amylin Pharmaceuticals has been acquired by Bristol-Myers Squibb
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top